IL-23抑制治疗慢性炎症性疾病
生物制剂单克隆抗体可抑制驱动不同器官系统慢性炎症性疾病的过度活跃细胞因子信号。过去10年,IL-23抑制剂在银屑病皮肤与关节疾病及炎症性肠病治疗中占据重要地位。该类药物针对这些疾病共享的上游病理机制,具有高疗效率和持久应答,给药间隔可延长至3个月。汇总临床试验数据显示,超过70%的银屑病患者和高达50%的炎症性肠病患者获得客观疾病改善。
要点
- IL-23抑制剂在银屑病和炎症性肠病中显示高疗效率和持久应答,给药间隔可延长至3个月。
- IL-23 p19抑制剂在生物制剂初治和经治患者中均引发临床应答,在斑块状银屑病中优于TNF-α抑制剂。
- IL-23抑制剂严重不良事件和感染发生率与安慰剂相似,长期安全性数据正在积累。
核心结论
- IL-23抑制剂针对银屑病皮肤与关节疾病及炎症性肠病共享的上游病理机制,具有高疗效率和持久应答;p19抑制剂在斑块状银屑病中优于TNF-α抑制剂,严重不良事件和感染发生率与安慰剂相似。
研究设计与样本
- 综述,总结IL-23抑制剂治疗慢性炎症性疾病的临床试验数据与文献。
主要发现
- 汇总临床试验数据显示,超过70%的银屑病患者和高达50%的炎症性肠病患者获得客观疾病改善。
- 首个IL-23A抗体抑制剂靶向与IL-12共享的p40亚基,后续针对IL-23A特有的p19蛋白的抑制剂显示出更大改善。
- IL-23 p19抑制剂在生物制剂初治和经治患者中均引发临床应答,在斑块状银屑病中优于TNF-α抑制剂。
- p19抑制剂之间报告的疗效差异提示个体药物作用可能受抗体亲和力调节。
- IL-23抑制剂严重不良事件和感染发生率在所有已批准适应症中与安慰剂相似,长期安全性数据正在积累。
关键数值与推荐
- IL-23抑制剂给药间隔可延长至3个月。
- 汇总临床试验数据:超过70%的银屑病患者和高达50%的炎症性肠病患者获得客观疾病改善。
- IL-23 p19抑制剂在斑块状银屑病中优于TNF-α抑制剂。
- IL-23抑制剂严重不良事件和感染发生率与安慰剂相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biological monoclonal antibody drugs inhibit overactive cytokine signalling that drives chronic inflammatory disease in different organ systems. In the last 10 years, interleukin (IL)-23 inhibitors have attained an important position in the treatment of psoriatic skin and joint disease as well as inflammatory bowel diseases. Addressing an upstream pathological mechanism shared between these disorders, this drug class has high efficacy rates and a durable response that extends dosing intervals up to 3 months. Pooled clinical trial data show objective disease improvement for more than 70% of patients with psoriasis and up to 50% of patients with inflammatory bowel disease. The first antibody inhibitor for IL-23A targeted a p40 subunit shared with IL-12. Subsequently, even greater improvement was established for inhibitors of the p19 protein unique to IL-23A. IL-23 p19 inhibitors elicit clinical response in both bio-naive and bio-exposed patients and show superiority to tumour necrosis factor α inhibitors in plaque psoriasis. Reported differences in efficacy between p19 inhibitors suggest that individual drug action might be modulated by antibody affinity. Although long-term safety data are accumulating, rates of serious adverse events and infections for interleukin (IL)-23 inhibitors are similar to the rates for placebo across approved indications.
引用
- Jairath V, Acosta Felquer ML, Cho RJ, et al. IL-23 inhibition for chronic inflammatory disease. Lancet. 2024. PMID: 39461795. doi:10.1016/S0140-6736(24)01750-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。